SCHEMBL4509705

SCHEMBL4509705

COC(=O)c1cccc(-c2nc(C(=O)c3ccc(N)c(OC)c3)n3ccc(C(=O)O)cc23)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4D Q08499 2/20 0.38
▸ AKT1 P31749 2/20 0.38
▸ AKT2 P31751 2/20 0.38
▸ HPGD P15428 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ RORC P51449 1/20 0.37
▸ SYK P43405 1/20 0.37
▸ MAP3K14 Q99558 3/20 0.36
▸ KDM5B Q9UGL1 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ ERN1 O75460 1/20 0.35
▸ CFTR P13569 1/20 0.35
▸ PLAU P00749 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1931533 0.91 AVPR2 (0.39) PDE4DAKT1AKT2SMN1; SMN2RORC
SCHEMBL1931163 0.89 CSNK2A2 (0.44) RORCMAP3K14NPC1MAPTMEN1
SCHEMBL1931204 0.88 RORC (0.43) PDE4DAKT1AKT2RORCMAP3K14
SCHEMBL1932541 0.87 RORC (0.50) RORCMAPT
SCHEMBL13918692 0.85 GAA (0.39) PDE4DHPGDHTTMAPTKMT2A
SCHEMBL4511201 0.81 KDM4E (0.35) PDE4DAKT1AKT2HPGDSMN1; SMN2
SCHEMBL4496043 0.81 PDE4D (0.38) PDE4DAKT1AKT2KDM5BNPC1
SCHEMBL1573248 0.80 TNK2 (0.38) PDE4DHTTRORCSYKNPC1
SCHEMBL322566 0.78 RORC (0.43) HPGDRORCMAPTCFTRPLAU
SCHEMBL4497581 0.78 ABCC9 (0.41) AKT1AKT2RORCSYKNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 — — US disclosed
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 — — US disclosed
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 — — US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 — — US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 — — US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 PDE4D 2003/4885AKT1 920/4885AKT2 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback